Abstract Library

#3009 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics

Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hautefeuille V

Authors: Hautefeuille V, Do Cao C, Coriat R, Dominguez S, Mineur L,

Keywords: Patients’ perception of information, Quality of Life, Lanreotide,

#2824 Patient and Nurse Satisfaction with the New Lanreotide Autogel Pre-Filled Syringe in Neuroendocrine Tumors (NET): A Prospective Study (SONATE)

Introduction: A new syringe (NS) for the delivery of lanreotide autogel was approved in Oct 2018 in France. The NS includes updated features (larger flanges, more robust plunger) intended to ease the injection.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Walter T, Eskenazi M, Rama N, Gueguen D, Mir O,

Keywords: neuroendocrine tumors, lanreotide, nursing, patient-reported outcomes,

#2791 NEN Skeletal Metastasis Performance and the Correlation with Cell Proliferation: 112 Cases of 68Ga-DOTA-TATE Results Analysis

Introduction: 68Ga-DOTA-TATE PET/CT plays an important role in neuroendocrine neoplasm(NEN)diagnosis and biological charecteristcs evaluation.Skeleton is the second common metastatic organ in NEN after liver and it affects the quality of patient’s life.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Yu J

Authors: Xie Q, Lu M, Li J, Li N, Yang Z,

Keywords: Neuroendocrine neoplasm, somatostatin receptor, PET/CT, Skeletal metastasis,

#2701 Assessing the Gaps in Experience and Knowledge of Australian Primary Health Care Professionals (GPs), in Treating and Caring for the Increasing Number of Australian Neuroendocrine Tumour (NET) Patients

Introduction: Conservatively,the incidence of NETs is 7 / 000' p.a, however,the prevalence of patients living with NETs is higher,40/000',making it the 2nd most common GI malignancy after colorectal cancer.Patients are living longer,however,with impaired quality of life.Management of debilitating symptoms such as diarrhoea,fatigue,anxiety,and flushing are complex and heterogenous.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Leyden S

Authors: Leyden S, Cummins M, Wakelin K,

Keywords: diagnosis, ongoing care, primary healthcare, NETs, quality of life, symptom management, NET symptoms,

#2111 Biliary Neuroendocrine Tumors: A Retrospective Analysis of 28 Patients Since 1991

Introduction: Biliary neuroendocrine tumors represent less than 1% of all neuroendocrine tumors (NETs), and the related clinical study is limited.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zheng Z

Authors: Zheng Z, Chen C, Xie Y, Zheng C, Li B,

Keywords: neuroendocrine tumor, neuroendocrine carcinoma, biliary tract,